Scientists have identified a promising new strategy to improve immunotherapy for a rare type of liver cancer. Researchers discovered that the cancer escapes immune attack by drawing T cells away from the tumor and trapping them in nearby fibrous tissue, preventing them from destroying cancer cells. In laboratory studies, the FDA-approved drug AMD3100 successfully released these trapped immune cells, allowing them to return and attack the tumor more effectively. The findings suggest that repurposing an existing drug could enhance the power of immunotherapy for patients with difficult-to-treat liver cancers. Further clinical studies will be needed to confirm its safety and effectiveness in patients.
Read more at ScienceDaily